The Hemophilia Managed Care Review Board^®

• Release Date: October 24, 2016
• Expiration Date: April 30, 2018
• Estimated Time to Complete Activity: 1.5 hours
• Compatible with all modern browsers and mobile devices

DISTINGUISHED FACULTY

Vanita K. Pindolia, PharmD, BCPS Vice President, Ambulatory Clinical Pharmacy Programs_PCM Henry Ford Health System/Health Alliance Plan of Michigan Click here for biography

Edmund Pezalla, MD, MPH Formerly National Medical Director for Pharmacy Policy and Strategy Aetna, Inc. Click here for biography

Jonathan Roberts, MD Associate Medical Director Bleeding and Clotting Disorders Institute (BCDI) Assistant Professor of Pediatrics University of Illinois College of Medicine at Peoria Click here for biography

James H. Ruble, PharmD, JD Associate Professor (Clinical), Pharmacotherapy University of Utah College of Pharmacy Click here for biography

Target Audience

• Medical directors and pharmacy directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with hemophilia including: physicians, pharmacists, registered nurses, and case managers

Statement of Need/Program Overview

Hemophilia is an expensive chronic condition with total annual costs that can average $250,000 or more for severe patients. Optimal outcomes requires a collaborative and coordinated patient experience. The collaborative team can include an insurer, Hemophilia Treatment Center (HTC), and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans and employers in meeting clinical and/or financial goals.

Educational Objectives
After completing this activity, the participant should be better able to:

• Apply current and evolving strategies used by managed care organizations (MCOs) and specialty pharmacy providers to facilitate high quality care for members with hemophilia
• Utilize the most recent clinical recommendations for the treatment of patients with hemophilia, including prophylactic factor replacement and the role of emerging agents
• Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
• Identify processes for MCOs and specialty pharmacy providers to improve communications with HTCs
• Employ methods that enable optimal cost management of factor replacement therapy to be realized by multiple hemophilia stakeholders including MCOs and specialty pharmacy providers

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the National Hemophilia Foundation, and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0809-9999-16-478-H01-P)

Type of Activity
Knowledge

Nursing Continuing Education

Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period October 24, 2016 through April 30, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA

Internet

FEE INFORMATION

There is no fee for this educational activity.